BioNanomatrix Signs CRADA for Diagnostics to Optimize Cancer Radiation Therapy
Company will use its whole genome analyzer to initially assess DNA damage.!--h2>
BioNanomatrix signed a multiyear CRADA with the Radiation Biology Branch at the NCI to develop methods to detect, identify, and quantify DNA damage caused by ionizing radiation.
"Radiation therapy remains a mainstay of cancer treatment, but clinicians are hindered in their efforts to deliver an optimal dose by a lack of information on the extent of damage to the patient from the radiation already administered," says Han Cao, Ph.D., CSO. "Under this CRADA, BioNanomatrix and NCI will collaborate to develop tools expected to dramatically improve monitoring and assessment of cancer therapies and therapeutic regimens, by allowing physicians to quantify easily and accurately the extent of DNA damage during treatment."
BioNanomatrix will use its whole genome analyzer, the Nanoanalyzer™. The company says this technology is unique in that it enables pan-genomic identification and analysis on a molecule-by-molecule basis, delivering single molecule sensitivity in a parallel format. The system provides ultrahigh-resolution analyses of DNA, RNA, and other proteins rapidly, comprehensively, and cost effectively, adds BioNanomatrix.
The CRADA is initially focused on employing the Nanoanalyzer to assess radiation-induced damage to DNA. If these initial efforts show positive results, further studies may be performed to assess DNA damage and repair resulting from other cancer therapies, including chemotherapy.